Provectus Biopharmaceuticals: 10% owner Pershing Edward exercised 13,216 shares

What happened

• Pershing Edward, listed as a 10% owner, converted or exercised a derivative to acquire 13,216 shares of Series D-1 Convertible Preferred Stock at $0.00 on Oct 3, 2026. The Form 4 also lists a related derivative disposition entry (amount not applicable) at $0.00 on the same date.
• Footnotes state that the 13,216 shares reflect conversion of the issuer's 2025 convertible promissory note into Series D-1 Preferred Stock on Oct 3, 2026.

Key details

• Transaction date and price: Oct 3, 2026; price per share reported $0.00.
• Filing date and report period: filed Oct 5, 2026; period of report Oct 3, 2026. The filing does not indicate it was late.
• Shares owned after the transaction: not specified in the Form 4 provided.
• Relevant footnotes:
  • Each share of Series D-1 Preferred Stock is convertible into 10 shares of common stock.
  • Series D-1 Preferred Stock will automatically convert into common stock on Dec 31, 2028, unless earlier converted.
  • The 2025 promissory note could have been voluntarily converted earlier and automatically converted into Series D-1 Preferred Stock twelve months after issuance; the note converted on Oct 3, 2026.

Why it may matter

• The Form 4 reports a derivative conversion/acquisition rather than a market purchase or sale; no sale of underlying common stock is reported here.
• The reporting person is a 10% owner, indicating a large holder status rather than an executive title.
• This filing does not show why the insider traded or why the company acted.